-
1
-
-
77951089891
-
-
International Diabetes Federation 4th edn
-
International Diabetes Federation. IDF Diabetes Atlas, 4th edn, 2009.
-
(2009)
IDF Diabetes Atlas
-
-
-
2
-
-
2342466734
-
Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030
-
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
-
(2004)
Diabetes Care
, vol.27
, pp. 1047-1053
-
-
Wild, S.1
Roglic, G.2
Green, A.3
Sicree, R.4
King, H.5
-
4
-
-
0036139487
-
Elevated blood pressure among U.S. Adults with diabetes, 1988-1994
-
Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am J Prev Med 2002;22:42-8.
-
(2002)
Am J Prev Med
, vol.22
, pp. 42-48
-
-
Geiss, L.S.1
Rolka, D.B.2
Engelgau, M.M.3
-
5
-
-
0035050460
-
Diabetes, hypertension, and cardiovascular disease: An update
-
Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 2001;37:1053-9.
-
(2001)
Hypertension
, vol.37
, pp. 1053-1059
-
-
Sowers, J.R.1
Epstein, M.2
Frohlich, E.D.3
-
7
-
-
77950511412
-
Executive summary: Standards of medical care in diabetes - 2010
-
American Diabetes Association
-
American Diabetes Association. Executive summary: Standards of medical care in diabetes - 2010. Diabetes Care 2010;33(Suppl 1):S4-10.
-
(2010)
Diabetes Care
, vol.33
, Issue.SUPPL. 1
-
-
-
8
-
-
54349117353
-
Canadian Diabetes Association clinical practice guidelines for the prevention and management of diabetes in Canada
-
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee
-
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32:51-201.
-
(2008)
Can J Diabetes
, vol.32
, pp. 51-201
-
-
-
9
-
-
57349160286
-
Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
-
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30.
-
(2009)
Diabetologia
, vol.52
, pp. 17-30
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
-
11
-
-
0024511329
-
Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM
-
Consoli A, Nurjhan, N, Capani, F, Gerich, J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989;38:550-7.
-
(1989)
Diabetes
, vol.38
, pp. 550-557
-
-
Consoli, A.1
Nurjhan, N.2
Capani, F.3
Gerich, J.4
-
12
-
-
0029133235
-
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
-
Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
-
(1995)
N Engl J Med
, vol.333
, pp. 550-554
-
-
Stumvoll, M.1
Nurjhan, N.2
Perriello, G.3
Dailey, G.4
Gerich, J.E.5
-
13
-
-
77649256227
-
Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: The DREAM trial
-
Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: The DREAM trial. Diabetes Care 2010;33:608-13.
-
(2010)
Diabetes Care
, vol.33
, pp. 608-613
-
-
Hanley, A.J.1
Zinman, B.2
Sheridan, P.3
Yusuf, S.4
Gerstein, H.C.5
-
14
-
-
18044366410
-
Adipokines: Molecular links between obesity and atheroslcerosis
-
Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: Molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005;288:H2031-41.
-
(2005)
Am J Physiol Heart Circ Physiol
, vol.288
-
-
Lau, D.C.1
Dhillon, B.2
Yan, H.3
Szmitko, P.E.4
Verma, S.5
-
16
-
-
69949093803
-
Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications
-
Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009;94:3171-82.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 3171-3182
-
-
Goldberg, R.B.1
-
17
-
-
0037324289
-
Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease
-
Marx N, Froehlich, J, Siam L, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:283-8.
-
(2003)
Arterioscler Thromb Vasc Biol
, vol.23
, pp. 283-288
-
-
Marx, N.1
Froehlich, J.2
Siam, L.3
-
18
-
-
0242543997
-
The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients
-
Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003;42:1757-63.
-
(2003)
J Am Coll Cardiol
, vol.42
, pp. 1757-1763
-
-
Sidhu, J.S.1
Cowan, D.2
Kaski, J.C.3
-
19
-
-
57149127132
-
A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: Study design and protocol
-
Gupta M, Braga MB, Verma S. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: Study design and protocol. Can J Cardiol 2008;24:e65-9.
-
(2008)
Can J Cardiol
, vol.24
-
-
Gupta, M.1
Braga, M.B.2
Verma, S.3
-
20
-
-
1642467862
-
Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: The Funagata study
-
Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: The Funagata study. Diabetes Care 2003;26:2015-20.
-
(2003)
Diabetes Care
, vol.26
, pp. 2015-2020
-
-
Daimon, M.1
Oizumi, T.2
Saitoh, T.3
-
21
-
-
0037031088
-
Adiponectin and development of type 2 diabetes in the Pima Indian population
-
Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-8.
-
(2002)
Lancet
, vol.360
, pp. 57-58
-
-
Lindsay, R.S.1
Funahashi, T.2
Hanson, R.L.3
-
22
-
-
23844549872
-
Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes
-
Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4542-8.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 4542-4548
-
-
Mantzoros, C.S.1
Li, T.2
Manson, J.E.3
Meigs, J.B.4
Hu, F.B.5
-
23
-
-
33644698960
-
Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: Data from the SAPHIR Study
-
Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: Data from the SAPHIR Study. Stroke 2005;36:2577-82.
-
(2005)
Stroke
, vol.36
, pp. 2577-2582
-
-
Iglseder, B.1
Mackevics, V.2
Stadlmayer, A.3
Tasch, G.4
Ladurner, G.5
Paulweber, B.6
-
24
-
-
0034096988
-
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients
-
Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
-
(2000)
Arterioscler Thromb Vasc Biol
, vol.20
, pp. 1595-1599
-
-
Hotta, K.1
Funahashi, T.2
Arita, Y.3
-
25
-
-
12744269196
-
Adiponectin and future coronary heart disease events among men with type 2 diabetes
-
Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54:534-9.
-
(2005)
Diabetes
, vol.54
, pp. 534-539
-
-
Schulze, M.B.1
Shai, I.2
Rimm, E.B.3
Li, T.4
Rifai, N.5
Hu, F.B.6
-
26
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
-
(2008)
N Engl J Med
, vol.359
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
-
27
-
-
0035908632
-
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
-
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
-
(2001)
JAMA
, vol.286
, pp. 327-334
-
-
Pradhan, A.D.1
Manson, J.E.2
Rifai, N.3
Buring, J.E.4
Ridker, P.M.5
-
28
-
-
2942670689
-
Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
-
Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
-
(2004)
Circulation
, vol.109
, pp. 2818-2825
-
-
Ridker, P.M.1
Wilson, P.W.2
Grundy, S.M.3
-
29
-
-
28444484666
-
Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM
-
Coppola G, Corrado E, Muratori I, et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol 2006;106:16-20.
-
(2006)
Int J Cardiol
, vol.106
, pp. 16-20
-
-
Coppola, G.1
Corrado, E.2
Muratori, I.3
-
30
-
-
33646439400
-
C-reactive protein is a strong independent predictor of death in type 2 diabetes: Association with multiple facets of the metabolic syndrome
-
Linnemann B, Voigt W, Nobel W, Janka HU. C-reactive protein is a strong independent predictor of death in type 2 diabetes: Association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006;114:127-34.
-
(2006)
Exp Clin Endocrinol Diabetes
, vol.114
, pp. 127-134
-
-
Linnemann, B.1
Voigt, W.2
Nobel, W.3
Janka, H.U.4
-
31
-
-
1842538093
-
C-reactive protein and incident cardiovascular events among men with diabetes
-
Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004;27:889-94.
-
(2004)
Diabetes Care
, vol.27
, pp. 889-894
-
-
Schulze, M.B.1
Rimm, E.B.2
Li, T.3
Rifai, N.4
Stampfer, M.J.5
Hu, F.B.6
-
32
-
-
33646381127
-
High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: A 7-year follow-up study
-
Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: A 7-year follow-up study. Diabetes Care 2006;29:329-33.
-
(2006)
Diabetes Care
, vol.29
, pp. 329-333
-
-
Soinio, M.1
Marniemi, J.2
Laakso, M.3
Lehto, S.4
Ronnemaa, T.5
-
33
-
-
0035856980
-
Biochemistry and molecular cell biology of diabetic complications
-
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
-
(2001)
Nature
, vol.414
, pp. 813-820
-
-
Brownlee, M.1
-
34
-
-
20844448886
-
Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease
-
Signorelli SS, Malaponte G, Libra, M, et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med 2005;10:1-6.
-
(2005)
Vasc Med
, vol.10
, pp. 1-6
-
-
Signorelli, S.S.1
Malaponte, G.2
Libra, M.3
-
35
-
-
0028906790
-
Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina
-
Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995;91:2125-31.
-
(1995)
Circulation
, vol.91
, pp. 2125-2131
-
-
Brown, D.L.1
Hibbs, M.S.2
Kearney, M.3
Loushin, C.4
Isner, J.M.5
-
36
-
-
0041315638
-
The receptor RAGE as a progression factor amplifying arachidonate- dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control
-
Cipollone, F, Iezzi, A, Fazia, M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation 2003;108:1070-7.
-
(2003)
Circulation
, vol.108
, pp. 1070-1077
-
-
Cipollone, F.1
Iezzi, A.2
Fazia, M.3
-
37
-
-
0038173265
-
High glucose alters matrix metalloproteinase expression in two key vascular cells: Potential impact on atherosclerosis in diabetes
-
Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: Potential impact on atherosclerosis in diabetes. Atherosclerosis 2003;168:263-9.
-
(2003)
Atherosclerosis
, vol.168
, pp. 263-269
-
-
Death, A.K.1
Fisher, E.J.2
McGrath, K.C.3
Yue, D.K.4
-
38
-
-
77955272826
-
Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial
-
Bertrand, OF, Poirier, P, Rodes-Cabau, J, et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial. Atherosclerosis 2010;211:565-73.
-
(2010)
Atherosclerosis
, vol.211
, pp. 565-573
-
-
Bertrand, O.F.1
Poirier, P.2
Rodes-Cabau, J.3
-
39
-
-
40049089939
-
Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with type 2 diabetes mellitus
-
Kadoglou N P, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, Alevizos M. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Diabet Med 2008;25:333-40.
-
(2008)
Diabet Med
, vol.25
, pp. 333-340
-
-
Kadoglou, N.P.1
Iliadis, F.2
Angelopoulou, N.3
Perrea, D.4
Liapis, C.D.5
Alevizos, M.6
-
40
-
-
0036481709
-
Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients
-
Yang, WS, Jeng, CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-80.
-
(2002)
Diabetes Care
, vol.25
, pp. 376-380
-
-
Yang, W.S.1
Jeng, C.Y.2
Wu, T.J.3
-
41
-
-
0037031267
-
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
-
Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
-
(2002)
Circulation
, vol.106
, pp. 679-684
-
-
Haffner, S.M.1
Greenberg, A.S.2
Weston, W.M.3
Chen, H.4
Williams, K.5
Freed, M.I.6
-
42
-
-
34247574161
-
Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes
-
Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR. Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res Clin Pract 2007;77:180-7.
-
(2007)
Diabetes Res Clin Pract
, vol.77
, pp. 180-187
-
-
Reynolds, L.R.1
Kingsley, F.J.2
Karounos, D.G.3
Tannock, L.R.4
-
43
-
-
33847403059
-
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes
-
e1-6
-
Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007;153:445 e1-6.
-
(2007)
Am Heart J
, vol.153
, pp. 445
-
-
Stocker, D.J.1
Taylor, A.J.2
Langley, R.W.3
Jezior, M.R.4
Vigersky, R.A.5
-
44
-
-
41749093666
-
Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus
-
Dolezalova R, Haluzik MM, Bosanska L, et al. Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. Physiol Res 2007;56:741-8.
-
(2007)
Physiol Res
, vol.56
, pp. 741-748
-
-
Dolezalova, R.1
Haluzik, M.M.2
Bosanska, L.3
-
45
-
-
33749498694
-
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
-
Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006;8:650-60.
-
(2006)
Diabetes Obes Metab
, vol.8
, pp. 650-660
-
-
Rosenstock, J.1
Rood, J.2
Cobitz, A.3
Biswas, N.4
Chou, H.5
Garber, A.6
-
46
-
-
79951672869
-
Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naive patients with type 2 diabetes
-
Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naive patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2011;119:63-8.
-
(2011)
Exp Clin Endocrinol Diabetes
, vol.119
, pp. 63-68
-
-
Kadoglou, N.P.1
Kapelouzou, A.2
Tsanikidis, H.3
Vitta, I.4
Liapis, C.D.5
Sailer, N.6
-
47
-
-
0027406191
-
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
-
Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
-
(1993)
Diabetes Care
, vol.16
, pp. 434-444
-
-
Stamler, J.1
Vaccaro, O.2
Neaton, J.D.3
Wentworth, D.4
-
48
-
-
22144477948
-
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials
-
Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-9.
-
(2005)
Arch Intern Med
, vol.165
, pp. 1410-1419
-
-
Turnbull, F.1
Neal, B.2
Algert, C.3
-
49
-
-
77950507168
-
Heart failure events with rosiglitazone in type 2 diabetes: Data from the RECORD clinical trial
-
Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010;31:824-31.
-
(2010)
Eur Heart J
, vol.31
, pp. 824-831
-
-
Komajda, M.1
McMurray, J.J.2
Beck-Nielsen, H.3
-
50
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
-
(2007)
N Engl J Med
, vol.356
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
51
-
-
77955013179
-
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study
-
Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study. Lancet 2010;376:103-11.
-
(2010)
Lancet
, vol.376
, pp. 103-111
-
-
Zinman, B.1
Harris, S.B.2
Neuman, J.3
|